glp 1 and sarcopenia Causes of frailty in people taking GLP1RAs Balancing weight and muscle loss

The integration of GLP-1 therapies into national treatment guidelines for type 2 diabetes and obesity supports their broad adoption

Glutathione is the most abundant non-protein thiol (compounds containing R-SH) in animal cells, with concentrations ranging from 0.5 to 10 mmol/L

The associated caloric loss also contributes to reductions in body weight by 2 to 3 kg on average, another traditional CV risk factor [15,17]

Blood pressure elevation occurs in less than 1% of users, primarily those with pre-existing hypertension

Ferroptosis is regulated by multiple cellular metabolic events, including redox homeostasis, iron metabolism, and amino acid metabolism [32, 33]